Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics

Rhea-AI Summary

Vivos Inc. (OTCQB: RDGL) announced on October 29, 2025 an expanded strategic collaboration with Exubrion Therapeutics to advance targeted radioactive isotope technology for multiple companion-animal indications.

Agreed areas include shared clinic relationships, licensing coordination, and manufacturing optimization, building on prior cooperation on device classification, clinician training modules, and educational seminars. Both CEOs said the partnership aims to align scientific and operational strengths to accelerate innovation across distinct veterinary therapy markets.

Kennewick, WA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced enhanced cooperation with Exubrion Therapeutics to advance the use of targeted radioactive isotope technology for multiple indications in companion animals.

The two companies have agreed to broaden their joint efforts in several key areas — including shared clinic relationships, licensing coordination, and manufacturing optimization. These initiatives build upon prior collaborations involving device classification, development of clinician training modules, and educational seminars.

“Our companies complement one another exceptionally well,” said Dr. Michael K. Korenko, Chief Executive Officer of Vivos Inc. “Exubrion’s focus on treating osteoarthritis pain in companion animals and Vivos’s work in cancer therapy represent distinct markets, enabling collaboration without competitive conflict. By aligning our scientific and operational strengths, we can accelerate innovation and efficiency across both organizations.”

Dr. Korenko added, “It is our shared responsibility to continuously pursue improvements that drive success. With only a limited number of companies developing therapeutic applications of radioactive isotopes, cooperative innovation is key to advancing this field.”

“I’m excited to collaborate with the Vivos team to help further this important work,” said Jennifer Kirk, Chief Executive Officer of Exubrion Therapeutics. “Together, we can accelerate progress in advancing the use of radioisotopes as a powerful and versatile technology platform with wide-ranging potential.”

About Vivos Inc.
Vivos Inc. (OTCQB: RDGL) is a radiotherapeutic company developing innovative isotope-based products for cancer treatment and other therapeutic applications. Its core technologies — RadioGel^® for human use and IsoPet^® for veterinary applications — are designed to precisely deliver therapeutic radiation to targeted tumor sites while minimizing exposure to surrounding healthy tissue. For more information, visit www.VivosInc.com.

About Exubrion Therapeutics
Exubrion Therapeutics is a veterinary radiotherapeutics company dedicated to improving the lives of companion animals through advanced radioisotope technology. The company’s lead product, Synovetin OA^®, is an innovative, minimally invasive treatment for osteoarthritis that targets the source of the disease and provides long-lasting joint pain relief. Learn more at www.Exubrion.com.

Michael K. Korenko, Sc.D.
Chief Executive Officer, Vivos Inc.
Email: MKorenko@RadioGel.com
Follow Vivos Inc. on X (Twitter): @VivosIncUSA
Learn more about RadioGel^® and IsoPet^® at www.VivosInc.com

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, identified by terms such as “will,” “expects,” “plans,” “anticipates,” and “intends.” These statements involve risks and uncertainties that could cause actual results to differ materially, including challenges in executing business strategies, economic conditions, competition, regulatory changes, delays in clinic certifications, and other factors beyond the control of Vivos Inc. For a detailed discussion of these risks, please refer to the company’s filings with the Securities and Exchange Commission.

FAQ

What did Vivos (RDGL) announce on October 29, 2025 regarding Exubrion Therapeutics?

Vivos announced an expanded collaboration with Exubrion to advance targeted radioactive isotope technology for multiple companion-animal indications, including shared clinics, licensing coordination, and manufacturing optimization.

How does the Vivos and Exubrion collaboration affect Vivos (RDGL) operations?

The companies said they will align scientific and operational strengths through shared clinic relationships, licensing coordination, and manufacturing optimization to accelerate innovation.

Which indications will Vivos (RDGL) and Exubrion focus on together?

The collaboration targets multiple companion-animal indications; Exubrion focuses on osteoarthritis pain while Vivos focuses on cancer therapy, enabling non-competitive collaboration.

Does the Vivos and Exubrion agreement include clinician training for RDGL-related technologies?

Yes, the expanded cooperation builds on prior work developing clinician training modules and educational seminars.

Who are the CEOs commenting on the Vivos (RDGL) and Exubrion partnership?

Vivos CEO Dr. Michael K. Korenko and Exubrion CEO Jennifer Kirk commented that the collaboration will accelerate progress in radioisotope therapeutic applications for companion animals.

Will the Vivos (RDGL) collaboration change manufacturing for radioisotope therapies?

The companies agreed to work on manufacturing optimization as part of the expanded cooperation to support therapeutic development.